Back to Report Store Home

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

  • Published: Jan-2015
  • Report Code: GBIHC352MR
  • Report Format: pdf


Colorectal Cancer (CRC) can take 10 to 15 years to develop, and many symptoms do not become apparent until the late stages of tumor development. Incidence is high; it is the third-most commonly diagnosed gastrointestinal tract cancer and the fourth leading cause of mortality among all cancers. Regionally, incidence is higher in the US and Europe than in Japan due to dietary differences, although incidence in Japan is rapidly increasing due to the westernization of the Japanese diet.

The marketed products landscape comprises a wide range of treatment options such as immunotherapies, chemotherapies, and targeted therapies. However, a lack of awareness and screening programs in the developed nations are barriers to improving the patient survival rate and reducing the cost of treatment


  • The current CRC market contains targeted therapies such as Avastin, Zaltrap, and a range of immunotherapy drugs.

  • Which factors contribute to the current market size?

  • Will Avastin continue to dominate as the first-line treatment option for CRC?

  • With 392 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage CRC.

  • Which small molecules are most prominent within the pipeline?

  • Do the upcoming therapies offer advantages over the commercially proven mechanisms?

  • How will upcoming therapies change the treatment paradigm in the near future?

  • Analysis of clinical trials since 2006 identified that CRC products have a high rate of attrition.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?

  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

  • Over the 2013–2020 forecast period, the CRC market in the eight major markets is expected to increase in value at a moderate CAGR of 1.8%, from $8.3 billion to just over $9 billion.

  • Which markets make the most significant contribution to the current market size?

  • What are the epidemiology trends in these markets?

  • Which factors will influence growth rates in the different major markets?

  • Will new market entrants lead to substantial changes in annual therapy costs?

  • Despite rising CRC incidence and new product approvals, generic sales erosion resulting from patent expirations will hamper market growth during the forecast period.

  • Which patent expirations will have the most significant impact on the market?

  • How will different treatment usage patterns affect growth in the major markets?

Reasons To Buy

  • Understand the clinical context of CRC by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.

  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

  • Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.

  • Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.

  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.

  • Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan.

  • Discover trends in licensing and co-development deals concerning CRC products and identify the major strategic consolidations that have shaped the commercial landscape.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments